{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"260"}]}],"title":"Progression-Free Survival (PFS)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"260"}]}],"title":"Time to Progression (TTP)"},{"categories":[{"measurements":[{"groupId":"OG000","value":"232"}]}],"title":"Duration of Overall Response (DR)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"groups":[{"description":"KW-0761: In the first treatment course KW-0761 will be administered i.v. once a week for four weeks, followed by a 2-week observation period. Subsequent treatment courses are permissible for subjects demonstrating a response or maintaining stable disease and will consist of an infusion of KW-0761 every other week.","id":"OG000","title":"KW-0761"}],"paramType":"NUMBER","populationDescription":"Safety Analysis Set: All subjects who received at least one dose of KW-0761 (even a partial dose).","reportingStatus":"POSTED","timeFrame":"one year","title":"Global Composite Response (Skin, Blood, Lymph Nodes)as Determined by Skin Evaluations, Blood Counts and PET/CT Imaging","type":"PRIMARY","unitOfMeasure":"days"}